Following on from information provided to NICE by the company in March 2018, the appraisal of Eltrombopag for untreated severe aplastic anaemia [ID1198] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1198

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in March 2018, the appraisal of Eltrombopag for untreated severe aplastic anaemia [ID1198] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
13 March 2018 Suspended. The company has informed NICE that they will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal whilst we consider the next steps

For further information on our processes and methods, please see our CHTE processes and methods manual